CN106265669A - Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof - Google Patents

Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof Download PDF

Info

Publication number
CN106265669A
CN106265669A CN201610632766.0A CN201610632766A CN106265669A CN 106265669 A CN106265669 A CN 106265669A CN 201610632766 A CN201610632766 A CN 201610632766A CN 106265669 A CN106265669 A CN 106265669A
Authority
CN
China
Prior art keywords
daidzein
hydroxycamptothecine
effect
cell
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610632766.0A
Other languages
Chinese (zh)
Inventor
包永明
郭建丽
姬芳玲
王静云
唐琴
李莹雪
姜波
安利佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian University of Technology
Original Assignee
Dalian University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian University of Technology filed Critical Dalian University of Technology
Priority to CN201610632766.0A priority Critical patent/CN106265669A/en
Publication of CN106265669A publication Critical patent/CN106265669A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a kind of pharmaceutical composition, its described pharmaceutical composition contains 10 hydroxy camptothecins and daidzein.The pharmaceutical composition of the present invention has significant synergistic effects in treatment gastric cancer, breast carcinoma, hepatocarcinoma, colon cancer etc., reduces dosage, improves the curative effect of medicine, decreases the generation of side effect.

Description

The drug regimen of daidzein and 10-hydroxycamptothecine and application thereof
Technical field
The present invention relates to a kind of antineoplastic pharmaceutical compositions, be specifically related to the medicine of daidzein and 10-hydroxycamptothecine Compositions and preparation treatment pulmonary carcinoma, cancer of pancreas, colon cancer, hepatocarcinoma, carcinoma of prostate, renal carcinoma, gastric cancer, cerebroma, sarcoma, ovary Application in the medicine of cancer or breast carcinoma.
Background technology
Along with the raising day by day of people's living standard, the sickness rate of cancer is also in cumulative year after year, and cancer has become threat people The big killer of the one of class health and lives.One research report of World Health Organization (WHO) shows, 20 years from now on, new tumor patient people Number will be increased to 15,000,000 by the most annual 10000000.It is annual that because of malignant tumor, the number of death also will be increased to by 6,000,000 10000000.According to Cancer in China report display in 2015, China had more than 2,800,000 people for 2015 and dies from cancer, average every day 7500 People.In addition to pulmonary carcinoma, gastric cancer, hepatocarcinoma, esophageal carcinoma and colon cancer are also modal cancers in Chinese male and women.In China's cancer Disease has become as first of the disease cause of the death, and M & M is all the most soaring, and public health is caused grave danger. Therefore, the treatment of cancer becomes problem urgently to be resolved hurrily.The method for the treatment of cancer mainly has operation, radiotherapy and chemotherapy, wherein at present The most frequently used still chemotherapy, but the dissolubility of most chemotherapeutics itself is poor, and toxic and side effects is strong, and action target spot is single, is easily generated Drug resistance, thus limit its clinical practice.The most how to improve the drug effect of these chemotherapeutics, reduce the secondary work of its poison simultaneously With, it is current urgent problem.And for reaching this purpose, most efficient method is through making chemotherapeutics and low toxicity Or nontoxic Drug combination, thus reach the effect of synergistic antitumor.
10-hydroxycamptothecine is that peculiar from China and that resource is the abundantest Fructus seu radix camptothecae acuminatae (Fructus Camptothecae Acuminatae), isolated antitumaous effect is the strongest One of Alkaloid.It is a kind of cell cycle specific agents, mainly acts on S phase cancerous cell, different by suppression topology The activity of structure enzyme I and make DNA break, thus suppress cell proliferation.This medicine is to multiple human malignant tumor cell such as gastric cancer, liver Cancer, rectal cancer etc. are respectively provided with lethal effect.Additionally, this kind of medicine and other conventional anticarcinogen are without crossing drug resistant, therefore to resistance to Medicine tumor has therapeutical effect.But its dissolubility is poor, and the shortcomings such as toxic and side effects are easily caused to limit its clinical practice.In order to solve These problems, this research and utilization its combine with other low cytotoxic drugs, thus reach the effect of attenuation synergistic.
Daidzein is white powder, is mainly derived from leguminous plant Herba Trifolii Pratentis herb, alfalfa herb, Radix Puerariae, big The seed of bean.Research shows that it has expansion blood vessel, increases coronary flow, reduces blood pressure, decreasing heart rate and reduction myocardial oxygen consumption Amount and arrhythmia, antibacterial, estrogen-like effects, treatment climacteric syndrome, osteoporosis, the effect such as anticancer, but greatly Bean aglycon list medicine antitumaous effect is the most weak, uses the daidzein of high dose just can play anticancer effect, therefore uses daiazi The single medicine of unit is anticancer and unrealistic.It is used for the most clinically treating climacteric syndrome, heart disease, cardiovascular diseases, sclerotin Loosen.Its toxicity of this exopathogenic factor is extremely low, cheap, is with a wide range of applications.
Up to the present, about 10-hydroxycamptothecine and daidzein being used in combination in antitumor and the two is anti- Synergism in tumor have not been reported.
Summary of the invention
It is an object of the invention to provide a kind of highly active antineoplastic pharmaceutical compositions and treat each carcinoid in preparation Application in the medicine of disease.
The antineoplastic pharmaceutical compositions of the present invention contains 10-hydroxycamptothecine and daidzein.
The structural formula of 10-hydroxycamptothecine, daidzein and puerarin is as shown in I, II, III.
10-hydroxycamptothecine is preferably 0.05~2:1 with the mol ratio of daidzein.
Antineoplastic pharmaceutical compositions of the present invention, preferably in the case of, described 10-hydroxycamptothecine and daidzein Valid density be respectively 0.3~25 μM and 5~20 μMs;In the case of preferred, the most respectively 3~13 μMs and 6~16 μMs.
Antineoplastic pharmaceutical compositions of the present invention, preferably in the case of, described 10-hydroxycamptothecine and daidzein Retarder thinner be dimethyl sulfoxide or ethanol.
The antineoplastic pharmaceutical compositions of the present invention can be applicable to treat all kinds of tumor, and described tumor includes but not limited to lung Cancer, cancer of pancreas, colon cancer, hepatocarcinoma, carcinoma of prostate, renal carcinoma, gastric cancer, cerebroma, sarcoma, ovarian cancer or breast carcinoma.
The application of described antineoplastic pharmaceutical compositions, preferably in the case of, described daidzein and 10-hydroxycamptothecine Add simultaneously;In the case of preferred, after adding, act on 30~50h simultaneously.
The method that the antineoplastic pharmaceutical compositions of the present invention can use this area conventional is made and is suitable to gastrointestinal administration or non- The preparation of gastrointestinal administration, preferably makes the preparation of gastrointestinal administration by this pharmaceutical composition, and its dosage form can be conventional Tablet, capsule, controlled or sustained release formulations.
10-hydroxycamptothecine in antineoplastic pharmaceutical compositions of the present invention and/or its derivant and daidzein and/or its Derivant can directly mix makes preparation;Or make preparation respectively, then according still further to ability with the mixing of corresponding adjuvant respectively The mode of territory routine is packed or combines;Or after mixing with corresponding adjuvant respectively, remix and make preparation.Preparation uses Adjuvant can use the conventional adjuvant in this area, but react with pharmaceutical composition of the present invention of getting along well or do not affect medicine of the present invention Premised on the curative effect of compositions.
According to dosage form and the difference of preparation specification, pharmaceutical composition of the present invention content in the formulation can be at 1- It is adjusted between 99wt%, preferably 10-90wt%.Additionally, the dosage of pharmaceutical composition of the present invention can be right according to being administered As the dosage form of, route of administration or medicine suitably changes, but to ensure this pharmaceutical composition energy in mammal body Premised on enough reaching effective blood drug level.
The pharmaceutical composition of the present invention has significant synergistic effects in treatment gastric cancer, breast carcinoma, hepatocarcinoma etc., improves The curative effect of medicine, reduces dosage, decreases the generation of side effect.
Accompanying drawing explanation
Fig. 1 is to show the two prescription used time variable concentrations figure to MCF7 cell inhibitory effect Yu fit equation;Wherein: A: big Bean aglycon is to MCF7 cell inhibitory effect figure;B: according between dosage and the breast carcinoma MCF7 cell survival rate of daidzein Relation be fitted the rectilinear that obtains;C:10-hydroxy camptothecin is to MCF7 cell inhibitory effect figure;D: according to 10-hydroxyl Relation between dosage and the MCF7 cell survival rate of camptothecine is fitted the rectilinear obtained;
Fig. 2 is to show that when 10-hydroxycamptothecine share from daidzein, variable concentrations is thin to MCF7 with different administration timing of drug The figure of born of the same parents' Proliferation Ability;Wherein: significance analysis is only to add HCPT medicine for comparison often organizing, if P < 0.05, then be significantly, table It is shown as " * ";If P < 0.01, then it is extremely notable, is expressed as " * * ".
Fig. 3 is to show the two prescription used time variable concentrations figure to gastric cancer BGC823 cell inhibitory effect Yu fit equation;Its In: A: daidzein is to BGC823 cell inhibitory effect figure;B: according to dosage and the BGC823 cell survival of daidzein Relation between rate is fitted the rectilinear obtained;C:10-hydroxy camptothecin is to BGC823 cell inhibitory effect figure;D: according to Relation between dosage and the BGC823 cell survival rate of 10-hydroxycamptothecine is fitted the rectilinear obtained;
Fig. 4 is to show that when 10-hydroxycamptothecine share from daidzein, variable concentrations and different administration timing of drug are to BGC823 The figure of cell inhibitory effect;Wherein: significance analysis is only to add HCPT medicine for comparison often organizing, if P < 0.05, then be significantly, It is expressed as " * ";If P < 0.01, then it is extremely notable, is expressed as " * * ".
Fig. 5 is the figure showing two prescription used time variable concentrations to proliferation of hepatocellular carcinoma HepG 2 cell line suppression with fit equation;Its In: A: daidzein is to HepG2 cell inhibitory effect figure;B: according to dosage and the HepG2 cell survival rate of daidzein Between relation be fitted the rectilinear that obtains;C:10-hydroxy camptothecin is to HepG2 cell inhibitory effect figure;D: according to 10- Relation between dosage and the HepG2 cell survival rate of hydroxy camptothecin is fitted the rectilinear obtained;
Fig. 6 is to show that when 10-hydroxycamptothecine share from daidzein, variable concentrations is thin to HepG2 with different administration timing of drug The figure of born of the same parents' Proliferation Ability;Wherein: significance analysis is only to add HCPT medicine for comparison often organizing, if P < 0.05, then be significantly, table It is shown as " * ";If P < 0.01, then it is extremely notable, is expressed as " * * ".
Fig. 7 is to show the two prescription used time variable concentrations figure to colon cancer Caco2 cell inhibitory effect Yu fit equation;Its In: A: daidzein is to Caco2 cell inhibitory effect figure;B: according to dosage and the Caco2 cell survival rate of daidzein Between relation be fitted the rectilinear that obtains;C:10-hydroxy camptothecin is to Caco2 cell inhibitory effect figure;D: according to 10- Relation between dosage and the Caco2 cell survival rate of hydroxy camptothecin is fitted the rectilinear obtained;
Fig. 8 is to show that when 10-hydroxycamptothecine share from daidzein, variable concentrations is thin to Caco2 with different administration timing of drug The figure of born of the same parents' Proliferation Ability;Wherein: significance analysis is only to add HCPT medicine for comparison often organizing, if P < 0.05, then be significantly, table It is shown as " * ";If P < 0.01, then it is extremely notable, is expressed as " * * ".
Fig. 9 is to show the variable concentrations figure to MCF7 cell inhibitory effect Yu fit equation when puerarin is alone;Wherein: A: Puerarin is to MCF7 cell inhibitory effect figure;B: enter according to the relation between dosage and the MCF7 cell survival rate of puerarin The rectilinear that row matching obtains;
Figure 10 is to show that when 10-hydroxycamptothecine share from puerarin, variable concentrations and different administration timing of drug are to MCF7 cell The figure of Proliferation Ability;Wherein: significance analysis is only to add HCPT medicine for comparison often organizing, if P < 0.05, then be notable, expression For " * ";If P < 0.01, then it is extremely notable, is expressed as " * * ".
In each figure, Daidzein represents that daidzein, Puerarin represent that puerarin, HCPT represent 10-hydroxycamptothecine.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further elaborated, but the present invention is not limited to this, without departing from this In the case of the thought of invention and objective, any change being done technical scheme all should fall into right of the present invention and want In seeking book limited range.
Biomaterial, medicine and experimental technique used in embodiment 1~5 are as follows:
Cell: MCF-7 (Breast cancer lines), BGC823 (human stomach cancer cell line), HepG2 (human hepatoma cell strain), Caco2 cell (human colon cancer cell strain) is commercially middle to be obtained, such as Shanghai Inst. of Life Science, CAS Cellular resources center.
Medicine: (Sichuan is tieed up for precise 10-hydroxycamptothecine (Dalian Mei Lun Bioisystech Co., Ltd), daidzein Ke Qi bio tech ltd) and puerarin (Wei Keqi bio tech ltd, Sichuan), with dimethyl sulfoxide or ethanol Dissolving respectively, being made into 10-hydroxycamptothecine concentration is 100mmol/L, and daidzein concentration is 800mmol/L, puerarin concentration Stock solution for 400mmol/L preserves at-20 DEG C, is diluted in table 1~14 cited during use by fresh culture medium Suitably concentration, the culture medium used in embodiment 1~4 is DMEM high glucose medium.
MTT detects cell proliferation: cell is in containing 10% hyclone, 100kU/L penicillin, 100mg/L streptomycin In DMEM high glucose medium, 37 DEG C, 5%CO2Under conditions of cultivate.After cell trypsinization, enter with blood cell counting plate Row counting.(cell inoculum concentration 8000-10000/hole, according to cell to be inoculated in 96 porocyte culture plates by every hole 100 μ L volume Size and the speed of growth select), 5%CO2, 37 DEG C of incubators cultivate 24h after add the testing sample of variable concentrations gradient, 5%CO2, 37 DEG C of incubators hatch 48 hours.Discarding culture medium, wash once with PBS, then every hole adds containing 0.5mg/mL The serum-free medium 100 μ L, 5%CO of MTT2, 37 DEG C of incubators hatch 4h.Culture medium in 96 orifice bores is sucked, so Rear every hole adds 100 μ L dimethyl sulfoxide.Detecting by microplate reader, detection wavelength is 570nm, and reference wavelength is 630nm.
The calculating of Combination index (CI):
(1) relational expression between dosage (D) and cell survival rate (fu) is determined
Survival rate (fu)=Medicine group OD value/Matched group OD value
Suppression ratio (fa)=1-survival rate (fu)
According to middle efficacious prescriptions formula: fa/fu=(D/Dm)m, taking the logarithm in both sides, obtains
Log (fa/fu)=m logD-m log Dm,
If b=m, a=-m be logDm, Y=log (fa/fu), X=logD,
Then dosage and cell survival rate relational expression are Y=bX+a (Dm is middle effect dosage).
The cell survival rate that when can record certain drug given alone by experiment, different dosing dosage is corresponding.To be administered Dosage and cell survival rate data substitute into above-mentioned Equation for Calculating and go out Y and X.These group data are carried out linear fit, calculates correspondence B value, a value, i.e. obtain the equation Y=bX+a of the dosage corresponding to this medicine and suppression ratio relation.
(2) Combination index (CI) is calculated
Middle effect dosage (Dm) and m value is tried to achieve by a, b value in aforesaid equation.
Efficacious prescriptions formula D=Dm (fa/fu) in utilization1/m, individually make when calculating the depression effect reaching two kinds of drug combinations With the theoretical dosage (D of two kinds of medicinesSingle 1、DSingle 2、DSingle 2)。
Combination index (CI): CI=D is calculated by following equationClose 1/DSingle 1+DClose 2/DSingle 2
(DClose 1And DClose 2It is two medicines every kind of medicine the most respective dosage when share, for testing actually used administration Dosage.)
Embodiment 1
(1) with containing 10% hyclone, 100kU/L penicillin, the DMEM high glucose medium culture medium of 100mg/L streptomycin Dilution daidzein and the concentration that 10-hydroxycamptothecine is table 1~5, the daidzein of variable concentrations and 10-hydroxy-camptothecin respectively During alkali alone, the experimental result to MCF7 inhibited proliferation is shown in Fig. 1 and table 1-2.
Table 1 daidzein MCF7 cell survival Relation Parameters under different dosing dosage calculates
Table 2 10-hydroxycamptothecine MCF7 cell survival Relation Parameters under different dosing dosage calculates
As a example by table 1, carry out calculation specifications, first show that daidzein acts on the survival rate of MCF7 cell, then according to giving Relation between pharmaceutical quantities and cell survival rate is fitted obtaining equation Y=1.12X-3.07, then b=1.12, a=-3.07, M=b=1.12, Dm=10(-a/m)=550.90
The relational expression of the theoretical dosage and cell survival rate of thus deriving daidzein is: DSingle 1=Dm (fa/fu )1/m=550.9 [(1-fu)/fu)]1/1.12
The relational expression of the theoretical dosage and cell survival rate that in like manner can obtain 10-hydroxycamptothecine is: DSingle 2=Dm (fa/ fu)1/m=16.91 [(1-fu)/fu)]1/0 . 92
(2) with the combination Synergistic of 10-hydroxycamptothecine, daidzein promotes that the experimental result of MCF7 cell death is divided It is not shown in Table 3 and Fig. 2.
Table 3 daidzein and 10-hydroxycamptothecine alone with drug combination time MCF7 cell survival rate and CI value
A: represent and add 10-hydroxycamptothecine effect 24h again after first adding daidzein effect 24h
B: represent that daidzein acts on 48h after 10-hydroxycamptothecine dosing simultaneously
C: represent and add daidzein effect 24h again after first adding 10-hydroxycamptothecine effect 24h
Drug combination has 3 kinds of results: cooperative effect, antagonistic effect and additive effect.The general Combination index CI of employing comes Judge concrete effect, CI value<1 thinks have cooperative effect, and CI thinks value=1 have additive effect, CI value>1 think have short of money Antiatherosclerotic effect, < 0.7 thinks have significant cooperative effect to CI value.It can be seen from the results above that daidzein and the happiness of 10-hydroxyl When tree alkali is administered simultaneously, CI value can reach between 0.2-0.5 under doses and proportioning, and now, Papillary is to MCF7 The lethal effect of cell has preferable synergism.If first with adding 10-hydroxycamptothecine work after daidzein effect 24h again The effect of antagonism is then presented with 24h, on the contrary then synergism, but its synergy is less than synergy during dosing simultaneously.Institute With, it should it is best that both are administered simultaneously then curative effect.
The calculating of explanation CI value as a example by group 4b in table 3:
12.5 μm ol/L daidzeins and 6.25 μm ol/L 10-hydroxycamptothecines share, cell survival rate during dosing simultaneously Fu is 40.8 ± 1.50%, then D closes 1=12.5 μM, and D closes 2=6.25 μM.
The above-mentioned theory dosage that fu=40.8% substitutes into daidzein and 10-hydroxycamptothecine respectively is deposited with cell In the relational expression of motility rate, can obtain
The mono-1=550.90 of D [(1-fu)/fu)] 1/1.12=768.09 μM
The mono-2=16.91 of D [(1-fu)/fu)] 1/0.92=25.34 μM
Substitute into the computing formula of Combination index (CI), can obtain
CI=D closes the mono-1+D of 1/D and closes the mono-3=12.5/768.09+6.25/25.34=0.26 of 3/D
Embodiment 2
(1) the dilutest with the DMEM high glucose medium containing 10% hyclone, 100kU/L penicillin, 100mg/L streptomycin Release daidzein and the concentration that 10-hydroxycamptothecine is table 4~6, the daidzein of variable concentrations and the list of 10-hydroxycamptothecine The experimental result of BGC823 inhibited proliferation is shown in Fig. 3 and table 4-5 by the used time.
Table 4 daidzein BGC823 cell survival Relation Parameters under different dosing dosage calculates
Table 5 10-hydroxycamptothecine BGC823 cell survival Relation Parameters under different dosing dosage calculates
The relational expression of the theoretical dosage and cell survival rate of in like manner deriving daidzein is:
DSingle 1=Dm (fa/fu)1/m=489.1 [(1-fu)/fu)]1/1 . 32
The theoretical dosage of 10-hydroxycamptothecine with the relational expression of cell survival rate is: DSingle 2=Dm (fa/fu)1/m= 10.32[(1-fu)/fu)]1/0 . 74
(2) daidzein promotes the experimental result of BGC-823 cell death with the Synergistic that combines of 10-hydroxycamptothecine It is shown in Table 6 and Fig. 4.
Table 6 daidzein and 10-hydroxycamptothecine alone with drug combination time BGC823 cell survival rate and CI value
During it can be seen from the results above that daidzein and 10-hydroxycamptothecine are administered simultaneously, CI value at doses and Can reach between 0.2-0.4 under proportioning, now, Papillary has the most collaborative work to the lethal effect of BGC823 cell With.If first then presenting the effect of antagonism with adding 10-hydroxycamptothecine effect 24h after daidzein effect 24h again, otherwise then assist Same-action is smaller, the most also there will be antagonism.So, it should it is best that both are administered simultaneously then curative effect.
Embodiment 3
(1) the dilutest with the DMEM high glucose medium containing 10% hyclone, 100kU/L penicillin, 100mg/L streptomycin Release daidzein and the concentration that 10-hydroxycamptothecine is table 7~9, the daidzein of variable concentrations and the list of 10-hydroxycamptothecine The experimental result of HepG2 inhibited proliferation is shown in Fig. 5 and table 7-9 by the used time.
Table 7 daidzein HepG2 cell survival Relation Parameters under different dosing dosage calculates
Table 8 10-hydroxycamptothecine HepG2 cell survival Relation Parameters under different dosing dosage calculates
The relational expression of the theoretical dosage and cell survival rate of in like manner deriving daidzein is:
DSingle 1=Dm (fa/fu)1/m=537.98 [(1-fu)/fu)]1/1.30
The theoretical dosage of 10-hydroxycamptothecine with the relational expression of cell survival rate is:
DSingle 2=Dm (fa/fu)1/m=50.12 [(1-fu)/fu)]1/0.30
(2) with the combination Synergistic of 10-hydroxycamptothecine, daidzein promotes that the experimental result of HepG2 cell death is shown in Table 9 and Fig. 6.
Table 9 daidzein and 10-hydroxycamptothecine alone with drug combination time HepG2 cell survival rate and CI value
During it can be seen from the results above that daidzein and 10-hydroxycamptothecine are administered simultaneously, CI value at doses and Can reach between 0.02-0.07 under proportioning, now, the lethal effect of HepG2 cell is had by Papillary the most significantly assists Same-action.If first then presenting the effect of antagonism with adding 10-hydroxycamptothecine effect 24h after daidzein effect 24h again, otherwise Then synergism is smaller, the most also there will be antagonism.So, it should it is best that both are administered simultaneously then curative effect.
Embodiment 4
(1) with containing 10% hyclone, 100kU/L penicillin, the DMEM high glucose medium culture medium of 100mg/L streptomycin Dilution daidzein and 10-hydroxycamptothecine is the concentration of table 10~12 respectively, when the daidzein of variable concentrations is alone pair The experimental result of Caco2 inhibited proliferation is shown in Fig. 7 and table 10, the variable concentrations HCPT experiment to Caco2 inhibited proliferation Result is shown in Fig. 7 and table 11.
Table 10 daidzein Caco2 cell survival Relation Parameters under different dosing dosage calculates
Table 11 10-hydroxycamptothecine Caco2 cell survival Relation Parameters under different dosing dosage calculates
The relational expression of the theoretical dosage and cell survival rate of in like manner deriving daidzein is: DSingle 1=Dm (fa/fu )1/m=6210.17 [(1-fu)/fu)]1/0 . 58
The relational expression of the theoretical dosage and cell survival rate that in like manner can obtain 10-hydroxycamptothecine is: DSingle 2=Dm (fa/ fu)1/m=13.89 [(1-fu)/fu)]1/0 . 84
(2) with the combination Synergistic of 10-hydroxycamptothecine, daidzein promotes that the experimental result of Caco2 cell death is divided It is not shown in Table 12 and Fig. 8.
Table 12 daidzein and 10-hydroxycamptothecine alone with drug combination time Caco2 cell survival rate and CI value
A: represent and add 10-hydroxycamptothecine effect 24h again after first adding daidzein effect 24h
B: represent that daidzein acts on 48h after 10-hydroxycamptothecine dosing simultaneously
C: represent and add daidzein effect 24h again after first adding 10-hydroxycamptothecine effect 24h
During it can be seen from the results above that daidzein and 10-hydroxycamptothecine are administered simultaneously, CI value at doses and Can reach between 0.2-0.6 under proportioning, now, the lethal effect of Caco2 cell is had by Papillary the most significantly works in coordination with Effect.If first then present the effect of antagonism with adding 10-hydroxycamptothecine effect 24h after daidzein effect 24h again, otherwise also There is synergism, but synergism is less than synergism when being administered simultaneously, so both should be administered simultaneously then that curative effect is Good.
Embodiment 5
(1) with containing 10% hyclone, 100kU/L penicillin, the DMEM high glucose medium culture medium of 100mg/L streptomycin Dilution puerarin and the concentration that 10-hydroxycamptothecine is table 13~14, increase MCF7 when the puerarin of variable concentrations is alone respectively The experimental result growing inhibitory action is shown in Fig. 9 and table 13, and the experimental result of MCF7 inhibited proliferation is shown in Fig. 1 by variable concentrations HCPT And table 2.
Table 13 puerarin MCF7 cell survival Relation Parameters under different dosing dosage calculates
The relational expression of the theoretical dosage and cell survival rate of in like manner deriving puerarin is: DSingle 1=Dm (fa/fu)1/m =719.69 [(1-fu)/fu)]1/0 . 77
The relational expression of the theoretical dosage and cell survival rate that in like manner can obtain 10-hydroxycamptothecine is: DSingle 2=Dm (fa/ fu)1/m=16.91 [(1-fu)/fu)]1/0.92
(2) puerarin promotes the experimental result of MCF7 cell death respectively with the combination Synergistic of 10-hydroxycamptothecine It is shown in Table 14 and Figure 10.
Table 14 puerarin and 10-hydroxycamptothecine alone with drug combination time MCF7 cell survival rate and CI value
A: represent and add 10-hydroxycamptothecine effect 24h again after first adding puerarin effect 24h
B: represent that puerarin acts on 48h after 10-hydroxycamptothecine dosing simultaneously
C: represent and add puerarin effect 24h again after first adding 10-hydroxycamptothecine effect 24h
It can be seen from the results above that puerarin and 10-hydroxycamptothecine are either administered simultaneously, or by different order It is administered, all shows antagonism.And puerarin and daidzein belong to isoflavone, there is common parent nucleus 3-phenyl chromone Structure, but puerarin does not show and has synergism with HCPT, and shows when daidzein acts on HCPT simultaneously The strongest synergism.

Claims (7)

1. an antineoplastic pharmaceutical compositions, it is characterised in that containing 10-hydroxycamptothecine and daidzein.
Antineoplastic pharmaceutical compositions the most according to claim 1, it is characterised in that described 10-hydroxycamptothecine and Semen sojae atricolor The mol ratio of aglycon is 0.03~2:1.
Antineoplastic pharmaceutical compositions the most according to claim 1, it is characterised in that described 10-hydroxycamptothecine and Semen sojae atricolor The concentration of aglycon is respectively 0.3~25 μM and 5~20 μMs.
Antineoplastic pharmaceutical compositions the most according to claim 1, it is characterised in that described daidzein is liked with 10-hydroxyl Tree alkali adds simultaneously.
Antineoplastic pharmaceutical compositions the most according to claim 4, it is characterised in that described daidzein is liked with 10-hydroxyl Tree alkali acts on 30~50h after adding simultaneously.
Antineoplastic pharmaceutical compositions the most according to claim 1, it is characterised in that described 10-hydroxycamptothecine and Semen sojae atricolor The retarder thinner of aglycon is dimethyl sulfoxide or ethanol.
7. in claim 1-6 antineoplastic pharmaceutical compositions described in any one at preparation treatment pulmonary carcinoma, cancer of pancreas, colon Application in the medicine of cancer, hepatocarcinoma, carcinoma of prostate, renal carcinoma, gastric cancer, cerebroma, sarcoma, ovarian cancer or breast carcinoma.
CN201610632766.0A 2016-08-04 2016-08-04 Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof Pending CN106265669A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610632766.0A CN106265669A (en) 2016-08-04 2016-08-04 Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610632766.0A CN106265669A (en) 2016-08-04 2016-08-04 Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof

Publications (1)

Publication Number Publication Date
CN106265669A true CN106265669A (en) 2017-01-04

Family

ID=57664747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610632766.0A Pending CN106265669A (en) 2016-08-04 2016-08-04 Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof

Country Status (1)

Country Link
CN (1) CN106265669A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317732A (en) * 2020-02-04 2020-06-23 牡丹江医学院 Pharmaceutical composition for preventing nephropathy of CT contrast agent and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1312712A (en) * 1998-07-15 2001-09-12 L·拉峰试验公司 Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents
CN103961353A (en) * 2014-04-25 2014-08-06 大连理工大学 Medicine composition of baicalein and 10-hydroxycamptothecine, and application of medicine composition
CN104876902A (en) * 2015-03-30 2015-09-02 大连理工大学 7-methylcyclohexane-5-(2'-amino) phenyl-chrysin, preparation method thereof and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1312712A (en) * 1998-07-15 2001-09-12 L·拉峰试验公司 Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents
CN103961353A (en) * 2014-04-25 2014-08-06 大连理工大学 Medicine composition of baicalein and 10-hydroxycamptothecine, and application of medicine composition
CN104876902A (en) * 2015-03-30 2015-09-02 大连理工大学 7-methylcyclohexane-5-(2'-amino) phenyl-chrysin, preparation method thereof and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
许旭东 等: "抗肿瘤药用植物有效成分研究概况", 《中国中药杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111317732A (en) * 2020-02-04 2020-06-23 牡丹江医学院 Pharmaceutical composition for preventing nephropathy of CT contrast agent and preparation method thereof

Similar Documents

Publication Publication Date Title
CN105963637B (en) Application of cryptotanshinone and curcumin in preparation of tumor treatment medicine
CN106963769A (en) The pharmaceutical composition and its application of inhibitor containing PI3K and PERK inhibitor
CN102552908B (en) Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof
CN103948689A (en) Medicinal composition for treating non-small cell lung cancer and application thereof
CN103179967A (en) Anti-tumor pharmaceutical composition
CN101433535A (en) Novel sensitive enhancement and synergistic substance for chemical treatment of tumor
CN104434939B (en) Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition
CN104013636A (en) Anti-tumor pharmaceutical use of pentacyclic triterpene saponin compounds of szechuan melandium root
CN101125140B (en) Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect
CN105476996A (en) Application of curcumin and afatinib for combined treatment of non-small cell lung cancer
CN105796638B (en) Application of oridonin and cryptotanshinone in preparation of leukemia treatment drug
CN106265669A (en) Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof
CN109481454B (en) Anti-tumor composition, application of anti-tumor composition in preparation of anti-tumor or cancer cell inhibiting medicine, and anti-tumor medicine
CN103961353B (en) The pharmaceutical composition of baicalin and 10-hydroxycamptothecine and application thereof
CN101879173B (en) Application of Corilagin in preparing anti-tumor drugs
CN103919850B (en) A kind of pharmaceutical composition and its application in antineoplastic is prepared
CN104876902B (en) 7 cyclohexyl methyl 5 (2 &#39; amino) phenyl Chrysins and its preparation method and application
CN107951888A (en) The drug regimen and its application of Afatinib and 10-hydroxycamptothecine
CN104146999B (en) Rubescensine A and Docetaxel attenuation synergistic antineoplastic pharmaceutical compositions and application thereof
CN102440987B (en) Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof
CN102357123A (en) Application of herba dicranostigmae alcohol extract in preparing medicines for resisting melanoma transfer
CN103479649B (en) A kind of pharmaceutical composition and application thereof
CN101428034A (en) Antineoplastic combined medicament with enhancing and poison-reducing character
CN101229158B (en) Medicine compounds for treating tumour and applications thereof
CN103463104A (en) Medicinal composition and its application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170104

WD01 Invention patent application deemed withdrawn after publication